title: [Prostate cancer: an update].
abstract: 2009 Has been a year of high profile publishing about prostate cancer (PCa): To call in the first instance the S3 guideline and the ERSPC. The ERSPC especially as the basis for that in addition to the detection of prostate cancer, the treatment must be differentiated; overtreatment in particular may be avoided through the implementation of active surveillance protocols. In radical prostatectomy (RPx), increasingly the therapeutic value of lymphadenectomy is detected. Current issues in radiation oncology concern the efficacy and indications of brachytherapy, dose escalation with external beam radiotherapy and the differential indication of adjuvant vs. salvage radiotherapy after RPx. Similarly, the indication for salvage RPx after primary radiotherapy. To mention in systemic therapy are the GnRH antagonists, the so-called super-antiandrogens and the different approaches to immunotherapy of prostate cancer.
authors.affiliation: Urologische Klinik und Poliklinik, Im Neuenheimer Feld 110, 69120 Heidelberg. hohenfellner@med.uni-heidelberg.de
authors.forename: M
authors.initials: M
authors.lastname: Hohenfellner
mesh_terms: D033441:Andrology / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008297:Male; D011468:Prostatectomy / Q000639:trends*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D011878:Radiotherapy / Q000639:trends*
references.citation: Eur Urol. 2009 May;55(5):1037-63
references.pmid: 19185977
references.citation: Cancer. 2009 Aug 15;115(16):3670-9
references.pmid: 19536890
references.citation: Lancet. 2010 Apr 24;375(9724):1437-46
references.pmid: 20398925
references.citation: J Clin Oncol. 2010 Jan 1;28(1):126-31
references.pmid: 19917860
references.citation: Eur Urol. 2009 Jul;56(1):89-96
references.pmid: 19403236
references.citation: BJU Int. 2009 Feb;103(4):448-53
references.pmid: 18778350
references.citation: J Clin Oncol. 2009 Jun 20;27(18):2924-30
references.pmid: 19433689
references.citation: Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18
references.pmid: 19616743
references.citation: N Engl J Med. 2010 Apr 1;362(13):1192-202
references.pmid: 20357281
references.citation: J Urol. 2009 Nov;182(5):2285-90
references.pmid: 19762048
references.citation: Eur Urol. 2009 Mar;55(3):617-28-6
references.pmid: 18499335
references.citation: Science. 2009 May 8;324(5928):787-90
references.pmid: 19359544
references.citation: Eur Urol. 2009 Jun;55(6):1251-65
references.pmid: 19297079
references.citation: J Urol. 2009 Mar;181(3):956-62
references.pmid: 19167731
references.citation: N Engl J Med. 2009 Mar 26;360(13):1320-8
references.pmid: 19297566
references.citation: Oncologist. 2009 Jan;14(1):40-51
references.pmid: 19144683
references.citation: J Urol. 2009 Apr;181(4):1665-71; discussion 1671
references.pmid: 19233394
references.citation: Surg Oncol. 2009 Sep;18(3):268-74
references.pmid: 19394814
references.citation: BJU Int. 2009 Dec;104(11):1580-4
references.pmid: 20053189
references.citation: Curr Opin Oncol. 2010 May;22(3):263-7
references.pmid: 20177381